Exagen Reports Q1 Revenue Growth, Maintains 12-Month Liquidity, Amends Debt Facility

summarizeSummary

Exagen Inc. reported an 11.7% increase in Q1 2026 revenue to $17.3 million, alongside a widened net loss, but management projects sufficient liquidity for the next 12 months, supported by an amended debt facility and available capital programs.

check_boxKey Events

• Q1 2026 Financial Performance

  Revenue increased 11.7% year-over-year to $17.3 million, with gross margin slightly improving to 59.0%. The net loss widened to $4.0 million from $3.8 million in Q1 2025, but net cash used in operating activities improved slightly to $10.4 million.

• Liquidity and Cash Runway

  Cash and cash equivalents decreased to $21.5 million as of March 31, 2026. Management believes existing capital resources are sufficient to fund obligations for at least the next twelve months. The company has access to an additional $40.0 million under its Perceptive Term Loan Facility, subject to revenue milestones.

• Debt Facility Amendment

  The Perceptive Term Loan Facility was amended in March 2026, terminating a $10.0 million tranche (Tranche C) and extending the availability of another $10.0 million tranche (Tranche B) to September 30, 2026. The company remains in compliance with all debt covenants.

• Warrant Activity and Dilution

  804,788 shares of common stock were issued from cashless warrant exercises during Q1 2026. The warrant liability decreased from $1.752 million to $0.767 million, partly due to a $0.1 million gain from the termination of 150,000 Tranche C warrants.

auto_awesomeAnalysis

This quarterly report provides detailed financial results for Q1 2026, confirming the previously announced revenue beat and offering critical updates on the company's liquidity, debt structure, and operational progress. While top-line revenue figures were known, the full financial statements reveal continued cash burn and significant reliance on future financing, making the 12-month liquidity projection and available debt tranches crucial for investors. The increased dependence on a few key suppliers also presents a notable risk.